AMRI Announces Increased Production of Hydroxychloroquine Sulfate for COVID-19 Treatment

News
Article

FDA approved hydroxychloroquine sulfate for emergency use as a treatment for some hospitalized patients with COVID-19.

AMRI, a contract research development and manufacturing organization, announced on April 30, 2020 that it will be increasing its production of hydroxychloroquine sulfate (HCQ) API at its Rensselaer, NY, manufacturing facility to assist in the fight against COVID-19.

According to a company press release, FDA approved HCQ for emergency use as a treatment for some hospitalized patients with COVID-19.

“We look forward to working with our drug product producers, government agencies, and associated health authorities globally to ensure access to this API, as needed,” said the company in the press release.

Source: AMRI

 

 

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
US tariff rate rising , trade policy , business graph and dollars banknote , tax calculation change | Image Credit: © janews094 - stock.adobe.com
Related Content